ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-IL-11 Monoclonal Antibody 9MW3811

Also written as “9MW3811 Injection” and “9MW3811 injection”.

Its studies are mostly in Cicatrix · Pulmonary Fibrosis · Idiopathic Pulmonary Fibrosis, led by Mabwell (Shanghai) Bioscience.

Drug pageAnti-IL-11 Monoclonal Antibody 9MW3811: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Apr 12, 20264 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Mabwell (Shanghai) Bioscience43 open or runningphase 2since Apr 12, 2026Feb 2, 2023Dec 2026phase 2 · NCT07576608

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 2, 2023First study: phase 1 study in Pulmonary FibrosisFirst studyNCT05740475 · 32 enrolled · Australia
  2. Jun 12, 20232 phase 1 studiesNCT05912049, NCT05911984
  3. Apr 12, 2026Phase 2 study in CicatrixPhase 2 reachedNCT07576608 · 30 planned · China

Ahead

  1. Dec 2026Primary completion: phase 2 study in CicatrixNCT07576608

TargetBeta

IL11 →read by rule
“A humanized monoclonal antibody directed against interleukin-11 (IL-11), ”NCIt, by rule

Other programs on IL11

ProgramCompanyFurthest phaseStudies
BI 765423Boehringer Ingelheimphase 23

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07576608Cicatrix · China2RecruitingDec 202630
NCT05912049Idiopathic Pulmonary Fibrosis · China1RecruitingDec 202324
NCT05911984Advanced Malignant Solid Tumor · China1Not yet recruitingMar 202427
NCT05740475Pulmonary Fibrosis · Australia1CompletedSep 14, 202332

How it is read

Names in the registry

  • “9MW3811 Injection”, 3 entries
  • “9MW3811 injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.